Please login to the form below

Not currently logged in
Email:
Password:

RPS criticises homeopathic treatments

The UK's Royal Pharmaceutical Society has criticised the marketing of homeopathic treatments in a response to a consultation from the MHRA

The UK's Royal Pharmaceutical Society (RPS) has criticised the marketing of homeopathic treatments in a response to a consultation from the Medicines and Healthcare products Regulatory Agency (MHRA).

The RPS said it 'expressed concerns that the public may not fully understand the principles on which homeopathy is based' with more regulation needed in terms of what information is provided on product labels.

Current rules allow labels to display claims based on the product's traditional homeopathic use, with the RPS recommending that these labels carry a statement that these efficacy claims are not based on the same requirements applied to conventional drugs.

Chief scientific advisor with the RPS, Jayne Lawrence, said: "Given the lack of clinical and scientific evidence to support homeopathy, the RPSGB does not endorse homeopathy as a form of treatment.

"The Society strongly believes that any advertising for any homeopathic product, regardless of its licensing status needs to include the statements that there is no scientific evidence for homeopathy nor any evidence to support the clinical efficacy of homeopathic products beyond a placebo effect."

Of particular concern was the use of the word 'medicine' in relation to homeopathy, with the RPS claiming this could be viewed by patients as legitimising homeopathic products as clinically approved treatments.

Confusion between homeopathic products and herbal remedies was also discussed, with the RPS requesting the MHRA make the difference between the two products clear to the public so a fully informed choice can be made.

4th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics